
Folk medicine practices must be preserved: Mandya University VC
He was speaking at a seminar and interactive session on 'Folk medicine in present times' held at Mandya University. The event was jointly organised by Karnataka Janapada Academy, Mandya University, Karnataka Sangha, and Janapada Janneyaru.
Mr. Shivachittappa spoke on the relevance of indigenous healing practices and stated that 'the use of naturally grown medicinal plants is still prevalent in many communities'.
'In the past, elders treated allergies with Amrutaballi decoctions, chickenpox with Tulsi-Amrutaballi mixtures, and leg swelling with Uttarayana Soppu poultices,' he claimed.
He stressed that primary care should begin at home, and communities should have basic knowledge about the medicinal plants around them.
Jayaprakash Gowda, president, Karnataka Sangha, urged the youth not to view success solely through academic achievements but through meaningful contributions to society. 'Folk art forms are on the verge of extinction. The youth must take an active role in preserving folk traditions,' he said.
Gollahalli Shivaprasad, president, Karnataka Janapada Academy, called for the revival of folk wisdom in today's context. 'Our relationship with plants and nature defines the essence of folk traditions. The responsibility of sustaining our cultural heritage lies with the youth. Are they living up to this role?' he asked.
Mangala S.C., president, Janapada Janneyaru; Veena B.N., registrar, and Yoganarasimhachari K., registrar (examinations) of Mandya University; folk scholars V.N. Shivaramu, R. Gow, D.K. Rajendra, and others were present.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New Indian Express
11 hours ago
- New Indian Express
Hyderabad startup reverses chronic liver failure in animal trials
HYDERABAD: A Hyderabad-based startup, Tulsi Therapeutics, has demonstrated the complete reversal of chronic liver failure in animal trials using an innovative stem cell-exosome therapy. Conducted on rats, the preclinical study showed 100% liver fibrosis reversal and zero mortality among treated subjects, in stark contrast to the untreated group that saw only 14% reversal and 43% deaths. Tulsi-28X is a first-in-class regenerative biologic derived from Wharton's Jelly mesenchymal stem cells and their native exosomes, a combination never before tested in any animal model globally. Tulsi Therapeutics, incubated at ASPIRE-BioNEST, University of Hyderabad, developed the platform entirely in India over three years. Chronic liver failure accounts for nearly 20% of all liver-related deaths globally, with liver transplantation being the only treatment. Founder and CEO of Tulsi Therapeutics Dr Sairam Atluri said, 'There have been individual successes with stem cells and exosomes, but we combined them because they operate through different mechanisms. This combination maximised the biological outcome and marks a major milestone for India's biotech sector.' Looking ahead, the chief scientific officer said the next goal is to initiate human clinical trials in partnership with Nizam's Institute of Medical Sciences (NIMS), with groundwork expected to take up to two years. The results were presented at the AASLD 2024 Liver Conference in San Diego and have also been accepted for publication in the Journal of Regenerative Medicine.


Hans India
18 hours ago
- Hans India
Hyderabad: City startup achieves global first in regenerative medicine for liver failure
Hyderabad: In a significant achievement for India's biotechnology sector, Tulsi Therapeutics, a startup incubated at ASPIRE-BioNEST at the University of Hyderabad, has announced the world's first successful animal trial of a novel stem cell-exosome combination therapy for chronic liver failure. The investigational product, Tulsi-28X, is a groundbreaking regenerative therapy derived from Wharton's Jelly mesenchymal stem cells and their native exosomes. It's a combination that has never been tested in any animal model worldwide. Although conceptualised in the United States, the platform was developed in India through three years of intensive research at ASPIRE-BioNEST. The preclinical trial, conducted in collaboration with global experts including Dr. Naga Chalasani (Indiana University, USA) and Dr. Ajay Duseja (PGIMER, Chandigarh), demonstrated 100% of the animals treated with Tulsi-28x showed reversal of liver fibrosis (indicating liver regeneration) resulting in zero deaths, compared to only 14% reversal (p<0.001) and 43% deaths (p<0.0066) in the untreated control group. 'This is a significant milestone for India's biotech industry,' said Dr. Sairam Atluri, Founder & CEO of Tulsi Therapeutics. 'ASPIRE-BioNEST provided a world-class platform that helped us translate our vision into scientific reality. While human trials are the next challenge, this study opens doors to a new class of biologics in liver disease.' Key results were presented at the prestigious AASLD 2024 Liver Conference in San Diego and accepted for publication in the Journal of Regenerative Medicine. Tulsi Therapeutics is recognised as the world's first biotech company developing a dual stem cell–exosome biologic. Tulsi-28X works by secreting regenerative proteins and growth factors, stimulating the repair of diseased liver tissue. 'We are committed to developing world-class yet affordable regenerative solutions,' said Dr. Ravi Bonthala, Chief Scientific Officer, Tulsi Therapeutics. 'Our next step is to take Tulsi-28X into human clinical trials in collaboration with Nizam's Institute of Medical Sciences (NIMS).' Chronic liver failure remains a serious public health concern in India, contributing to nearly 20% of global liver-related deaths. With transplantation being the only current treatment, Tulsi-28X represents a potential paradigm shift. 'This milestone highlights how India's innovation ecosystem—anchored by institutions like the University of Hyderabad and enabled by BIRAC and incubators like ASPIRE-BioNEST—is capable of delivering breakthrough global biotech products,' said Prof. B.J. Rao, Vice Chancellor, University of Hyderabad. 'It reflects the power of science, policy, and startup synergy.' 'Tulsi Therapeutics' achievement is a proud moment for all of us at ASPIRE-BioNEST,' said Dr. Anil Kondreddy, CEO, ASPIRE-BioNEST. 'It reflects our mission to nurture science-led innovation with real-world impact. Being rooted in the University of Hyderabad gives us the strength of academic excellence, and it's incredibly fulfilling to see this ecosystem support a global-first breakthrough in regenerative medicine. This is precisely the kind of outcome we work to enable.'


Time of India
a day ago
- Time of India
City startup incubated at UoH develops stem cell treatment for chronic liver failure
Hyderabad: A startup incubated at the University of Hyderabad (UoH) successfully tested a new treatment for chronic liver failure using stem cells. Called Tulsi-28X, the treatment is touted to be the first in the world by the firm to use a special combination of stem cells and natural healing particles called exosomes. These are taken from a part of the umbilical cord known as Wharton's Jelly. Although the concept was born in the US, the entire platform was developed in India by Tulsi Therapeutics after three years of rigorous research at ASPIRE-BioNEST, UoH's biotech incubator. "We have done trials on rats. All animals treated with Tulsi-28X showed reversal of liver fibrosis, indicating liver regeneration, resulting in zero deaths, compared to only 14% reversal and 43% deaths in the untreated control group," Dr Sairam Atluri, founder & CEO of Tulsi Therapeutics, told TOI. The preclinical trial was conducted in collaboration with Indiana University, US, and PGIMER, Chandigarh. He said that this treatment method can be a game-changer as it would give a new lease of life to those with liver failure and waiting for transplantation. "Right now, the only treatment for liver failure is transplant. However, there are not enough donors, the treatment is very expensive, and it comes with various complications. The medicine that we developed can be administered intravenously," added Atluri, and said he moved from the US to India to work on this idea and bring it to life. You Can Also Check: Hyderabad AQI | Weather in Hyderabad | Bank Holidays in Hyderabad | Public Holidays in Hyderabad The startup has applied to the Central Drugs Standard Control Organisation (CDSCO) for conducting human trials. "We are committed to developing world-class yet affordable regenerative solutions," said Dr Ravi Bonthala, chief scientific officer of the startup. "Our next step is to take Tulsi-28X into human clinical trials in collaboration with Nizam's Institute of Medical Sciences."